Expert Q&A
Prepare the questions that need specialist judgement.

Ask the question that changes the decision.
Proposed experts have not been interviewed. These are research-backed questions and answer frameworks.
Proposed experts and areas of expertise →What exactly is the clinic buying—and which expenditure can it control?
Read the question & evidence →02Can clinics still prescribe compounded semaglutide or tirzepatide after the shortage—and what would justify this particular preparation?
Read the question & evidence →03Can a clinic buy compounded GLP-1 medicine for office use from a 503B outsourcing facility?
Read the question & evidence →04What evidence converts ‘nationwide coverage’ into a reliable state-expansion plan?
Read the question & evidence →05What does a credible GLP-1 supplier quality review contain beyond licences and a certificate of analysis?
Read the question & evidence →06Who owns cold-chain failures, concentration changes and dosing-instruction errors?
Read the question & evidence →07Which DSCSA and provenance responsibilities apply to this arrangement?
Read the question & evidence →08When is manufacturer-linked access preferable to an integrated pharmacy partner?
Read the question & evidence →09How should a clinic compare GLP-1 pharmacy quotes without being misled by introductory prices?
Read the question & evidence →10What should ‘cost per successfully fulfilled patient-month’ actually mean?
Read the question & evidence →11Which service levels reveal whether a pharmacy can support our growth?
Read the question & evidence →12Is our backup pharmacy genuinely independent—and can it absorb a disruption?
Read the question & evidence →13How do we change pharmacy partners without turning an operational migration into an unsafe treatment switch?
Read the question & evidence →14Which contract clauses protect continuity when regulation, price or performance changes?
Read the question & evidence →15What data and integration rights does the clinic need without misclassifying HIPAA relationships?
Read the question & evidence →16Could referral fees, prescribing incentives or exclusivity undermine the arrangement?
Read the question & evidence →The full interview brief
What should buyers establish before discussing price?
Start with the exact product, facility, patient destination and transaction—not a supplier category.
Read →Which developments should experts address explicitly?
Do not let an interview recycle shortage-era assumptions.
Read →Which recognised experts should the desk approach?
Recruit complementary expertise and disclose interests.
Read →1. What exactly is the clinic buying—and which expenditure can it control?
Framing: classify the transaction before discussing savings.
Read →2. Can clinics still prescribe compounded semaglutide or tirzepatide after the shortage—and what would justify this particular preparation?
Framing: a prescription, added ingredient or lower price is not automatic clearance.
Read →3. Can a clinic buy compounded GLP-1 medicine for office use from a 503B outsourcing facility?
Framing: resolve product eligibility independently of the facility’s registration.
Read →4. What evidence converts ‘nationwide coverage’ into a reliable state-expansion plan?
Framing: verify each relevant facility and permission, then test operational acceptance.
Read →5. What does a credible GLP-1 supplier quality review contain beyond licences and a certificate of analysis?
Framing: evaluate the facility and its corrective-action history, not the attractiveness of its compliance pack.
Read →6. Who owns cold-chain failures, concentration changes and dosing-instruction errors?
Framing: examine the complete handoff from prescription to patient use.
Read →7. Which DSCSA and provenance responsibilities apply to this arrangement?
Framing: assign obligations by activity and product before buying traceability software.
Read →8. When is manufacturer-linked access preferable to an integrated pharmacy partner?
Framing: compare the patient journey and clinic workload, not just the medicine price.
Read →9. How should a clinic compare GLP-1 pharmacy quotes without being misled by introductory prices?
Framing: compare equivalent, clinician-defined scenarios over a common time horizon.
Read →10. What should ‘cost per successfully fulfilled patient-month’ actually mean?
Framing: use a defined operational measure, not the phrase ‘successfully treated’ as a proxy for delivery.
Read →11. Which service levels reveal whether a pharmacy can support our growth?
Framing: measure the whole process and the separate stages within it.
Read →12. Is our backup pharmacy genuinely independent—and can it absorb a disruption?
Framing: test shared dependencies and usable capacity rather than counting supplier names.
Read →13. How do we change pharmacy partners without turning an operational migration into an unsafe treatment switch?
Framing: separate a pharmacy transfer from a change in medicine, formulation, concentration or device.
Read →14. Which contract clauses protect continuity when regulation, price or performance changes?
Framing: negotiate the exit process as carefully as the entry price.
Read →15. What data and integration rights does the clinic need without misclassifying HIPAA relationships?
Framing: determine each party’s role and permitted use of data before prescribing a standard agreement.
Read →20 pages shown
What remains unverified?
This research establishes an interview agenda and source-backed context, not a supplier shortlist or legal clearance.
Read →Sources
Regulation, safety and state requirements 1.
Read →Research quality self-assessment
The research’s own assessment; not an external rating.